azalanstat

Azalanstat (RS 21607) 是一种可口服的选择性哺乳动物羊毛甾醇 14-α-脱甲基酶抑制剂，具有降胆固醇活性,通过抑制细胞色素 P450 酶羊毛甾醇 14 α-去甲基化酶来抑制 HepG2 细胞、人成纤维细胞、仓鼠肝细胞和仓鼠肝脏中的胆固醇合成。

BR103 is a C3aR-selective agonist that is metabolically stable.

Azalanstat HCl is an anti-obesity drug acting as a lanosterol 14α-demethylase inhibitor. Azalanstat HCl has been shown to inhibit cholesterol synthesis in HepG2 cells, human fibroblasts, hamster hepatocytes and hamster liver, by inhibiting the cytochrome P450 enzyme lanosterol 14 alpha-demethylase. When administered orally to hamsters fed regular chow, RS-21607 (50 mg kg day) lowered serum cholesterol in a dose-dependent manner (ED50 = 62 mg kg) in a period of 1 week. It preferentially lowered low density lipoprotein (LDL) cholesterol and apo B relative to high density lipoprotein (HDL) cholesterol and apo A-1.

Azalanstat mesylate is an anti-obesity drug acting as a lanosterol 14α-demethylase inhibitor. Azalanstat mesylate has been shown to inhibit cholesterol synthesis in HepG2 cells, human fibroblasts, hamster hepatocytes and hamster liver, by inhibiting the cytochrome P450 enzyme lanosterol 14 alpha-demethylase. When administered orally to hamsters fed regular chow, RS-21607 (50 mg kg day) lowered serum cholesterol in a dose-dependent manner (ED50 = 62 mg kg) in a period of 1 week. It preferentially lowered low density lipoprotein (LDL) cholesterol and apo B relative to high density lipoprotein (HDL) cholesterol and apo A-1.

Ici D8731 is a nonpeptide angiotensin II antagonist with potential as a treatment for hypertension and heart failure.

(2R,4S)-Azalanstat (Iso-Azalansta) 是一种选择性血红素加氧酶 （HO）抑制剂，可用于研究心血管疾病。